Yixintang Pharmaceutical Group (002727) Fundamentals 2026 — P/E 23.6x, Revenue Analysis | SniperIQ
Yixintang Pharmaceutical Group (002727) is a CN-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥6.7B, trading at ¥11.38 on the SHZ. This SniperIQ fundamentals page covers Yixintang Pharmaceutical Group's valuation (P/E 23.6x, P/B 0.9x), profitability (net margin 1.6%), revenue (¥17.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Yixintang Pharmaceutical Group's market cap?
Yixintang Pharmaceutical Group (002727) has a market capitalization of approximately ¥6.7B, trading at ¥11.38 on the SHZ. Market cap moves with the live share price.
What is Yixintang Pharmaceutical Group's P/E ratio?
Yixintang Pharmaceutical Group's trailing twelve-month P/E ratio is 23.6x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Yixintang Pharmaceutical Group?
Yixintang Pharmaceutical Group runs a net profit margin of 1.6%, a gross margin of 33.0%, and an operating margin of 2.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Yixintang Pharmaceutical Group generate?
Yixintang Pharmaceutical Group reported revenue of ¥17.3B for fiscal year 2025, with net income of ¥263M and earnings per share (EPS) of 0.46. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Yixintang Pharmaceutical Group pay a dividend?
Yixintang Pharmaceutical Group offers a trailing dividend yield of about 3.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Yixintang Pharmaceutical Group financially healthy?
Yixintang Pharmaceutical Group carries a debt-to-equity ratio of 0.52x and a current ratio of 1.34x, with a market beta of 0.67. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Yixintang Pharmaceutical Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Yixintang Pharmaceutical Group (002727) the key facts are: market cap ¥6.7B, P/E 23.6x, revenue ¥17.3B, 52-week range 9.41-15.8. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Yixintang Pharmaceutical Group's full fundamentals live
Get Yixintang Pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.